MG
NRIX icon

Michael Gelband’s Nurix Therapeutics NRIX Stock Holding History

Michael Gelband’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-62,503
Closed -$969K – 1914
2026
Q1 		$969K Buy
+62,503
New +$1.04M 0.01% 1014
2025
Q4 		– Sell
-130,130
Closed -$1.2M – 1902
2025
Q3 		$1.2M Sell
130,130
-63,364
-33% -$658K 0.01% 896
2025
Q2 		$2.2M Buy
193,494
+174,326
+909% +$1.88M 0.02% 714
2025
Q1 		$228K Sell
19,168
-66,494
-78% -$1.11M ﹤0.01% 1278
2024
Q4 		$1.61M Buy
85,662
+51,049
+147% +$1.17M 0.01% 795
2024
Q3 		$778K Sell
34,613
-285,939
-89% -$6.48M ﹤0.01% 1048
2024
Q2 		$6.69M Buy
320,552
+154,949
+94% +$2.41M 0.05% 324
2024
Q1 		$2.43M Sell
165,603
-132,166
-44% -$1.42M 0.02% 625
2023
Q4 		$3.07M Buy
297,769
+247,621
+494% +$1.7M 0.02% 454
2023
Q3 		$394K Buy
50,148
+8,430
+20% +$77K ﹤0.01% 1320
2023
Q2 		$417K Buy
+41,718
New +$425K ﹤0.01% 1421
2022
Q4 		– Sell
-25,954
Closed -$338K – 1965
2022
Q3 		$338K Buy
+25,954
New +$411K ﹤0.01% 1491
2022
Q2 		– Sell
-15,034
Closed -$211K – 2281
2022
Q1 		$211K Buy
+15,034
New +$267K ﹤0.01% 1888
2021
Q4 		– Sell
-10,747
Closed -$322K – 2468
2021
Q3 		$322K Buy
+10,747
New +$332K ﹤0.01% 1589

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Michael Gelband's NRIX Position: Q2 2026 in Review

Michael Gelband sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 62,503 shares — an estimated $969K sold.

Michael Gelband first reported a position in NRIX in Q3 2021 and held it in 14 quarters. The position peaked at $6.69M in Q2 2024. 210 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Michael Gelband reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 62,503 Nurix Therapeutics shares in Q2 2026, an estimated $969K.
  • Michael Gelband first reported a position in Nurix Therapeutics in Q3 2021 and held it in 14 quarters.
  • Michael Gelband's Nurix Therapeutics position peaked at $6.69M in Q2 2024.
  • 210 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.